Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RuxCoFlam: Ruxolitinib in COVID-19 Hyperinflammation
NCT04338958Phase 2Completed
- Sponsor
- Friedrich Schiller University Jena
- Start
- Apr 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in coronavirus disease 2019 (COVID-19), sponsored by Friedrich Schiller University Jena. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04338958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338958.